GREAT ARTICLE in Fortune magazine on Biotech. PMCB is a perfect example of an up and coming company with the ability to become a GIANT in Licensing and changing the way Medicine treats Disease.
fortune.com/2015/03/09/biotech-pros-top-8-stock-picks/
fortune.com/2015/03/09/biotech-pros-top-8-stock-picks/
Quote:Biotech investing is largely an all-or-nothing kind of activity: Drugs either work or they don’t, says Deresiewicz. And when they truly benefit patients, they can deliver explosive, grand-slam growth. “My belief is firmly that the real sweet spot for making money in biotech is in the transition from obtuse asset to asset,” he says.
As a result, most biotech bulls try to focus on companies with huge future growth potential rather than worrying about today’s meager or nonexistent income. “Where are the pockets of unmet need in the world today? Is it another app for our smartphone, or is it going out and curing one of the diseases that has plagued humanity for centuries?” asks Finny Kuruvilla, a doctor-turned-investor who runs the No. 1–ranked $1.3 billion Eventide Gilead Fund, with 25% in biotech
